Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of Genetic Ancestry on the Efficacy and Toxicity of Idecabtagene Vicleucel in Patients with Relapsed/Refractory Multiple Myeloma

  • By

  • Christen M. Dillard

  • Hans Lee

  • Nilesh Kalariya

  • Naveen Subramanian

  • Oren Pasvolsky

  • Christopher Ferreri

  • Mahmoud Gaballa

  • Sheeba K. Thomas

  • Donna M. Weber

  • Melody Becnel

  • Gregory Kaufman

  • Muzaffar Qazilbash

  • Robert Z. Orlowski

  • Michelle A. T. Hildebrandt

  • Krina K. Patel

  • April 13, 2026

Share

Original Source(s)

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

  • by Christen M. Dillard, Hans Lee, Nilesh Kalariya, Naveen Subramanian, Oren Pasvolsky, Christopher Ferreri, Mahmoud Gaballa, Sheeba K. Thomas, Donna M. Weber, Melody Becnel, Gregory Kaufman, Muzaffar Qazilbash, Robert Z. Orlowski, Michelle A. T. Hildebrandt, Krina K. Patel

  • April 13, 2026

Related Content

The Effectiveness of Digital Intervention on Psychological Resilience in Postoperative Breast Cancer Patients During Chemotherapy Intervals: Quasi-Experimental Study

AI-Designed Binder Improves CAR T Cell Activity in Mice

Researchers screened 1,758 de novo protein binders and identified design features that influence CAR T cell activation, specificity, and tumor control

  • September 15, 2026

  • 3 min
Comment on “Life’s essential 8 and specific cancer risk and mortality in men and women: a population-based cohort analysis of 332,417 United Kingdom participants” and the inclusion of sleep in cancer focused guidelines